Heart-Safe prostate cancer treatment? new trial pits two hormone combos

NCT ID NCT06650579

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two different hormone therapy combinations (leuprolide plus abiraterone vs. relugolix plus abiraterone) in men with advanced prostate cancer who are also receiving radiation therapy. The goal is to see which combination causes less damage to the heart and blood vessels. Researchers will use CT scans and blood tests to monitor heart health over time. The trial enrolls 72 men with non-metastatic or biochemically recurrent prostate cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT PROSTATE CARCINOMA STAGE III PROSTATE CANCER AJCC V8 STAGE IVA PROSTATE CANCER AJCC V8

Contacts and locations

Locations

Emory Proton Therapy Center
RECRUITING

Atlanta, Georgia, 30308, United States
Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Winship at Emory Midtown
RECRUITING

Atlanta, Georgia, 30308, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.